Insider Purchases: Inside the Buy
Tag: Funanc1al Edge
Two Directors Bought Shares of Everest Group (EG) Cheaper Than the CEO Did 6 Months Ago: Will Buying Now Culminate in Profits?
Two Everest Group directors just bought stock around $306–$307—below the CEO’s June buy—while the company cleans house with a $1.2B adverse development cover and a renewal-rights sale to AIG. Institutions own essentially all the float, short interest is low, and forward P/E looks cheap. Here’s the risk/reward.
Investor & Insider James Breyer Just Bought Blackstone (BX). Should You Sip the Alt-Assets Kool-Aid—or Sit It Out?
Blackstone remains the alt-assets apex predator: $1.24T AUM, rising perpetual capital, and a fresh insider buy from director James Breyer. We unpack fundraising momentum, distributable earnings, variable dividends, key risks (rates, exits), and why dips may be gifts for long-term investors.
CEO Bought Shares of Booz Allen Hamilton: Time to Indulge
Booz Allen just flashed insider conviction: CEO Horacio Rozanski purchased ~$2M of BAH stock. Despite near-term revenue pressure from funding delays, the firm sports a record backlog, mission-critical AI/cyber programs, and steady capital returns. We unpack the bull/bear, valuation, and what could flip the narrative from pause to play.
CEO, COB, President All Bought Shares of FTI Consulting (FCN). It’s the Same Person—Still… Should You Buy Too?
FTI Consulting just posted record EPS while its tri-titled chief bought $1.13M of stock and the board added $500M to buybacks. A cycle-balanced franchise that compounds through booms, busts, and boardroom “oh-no’s.”
CEO Buys Shares of CSX. Should You Board Or Stay Off-Track?
CEO buy signal, steady margins, and intermodal momentum—yet top line is flat-ish and valuation looks fair. Our fun + smart breakdown with TL;DR & FAQs.
CEO Bought Shares At Twice Today’s Price: Time To Buy Iridium Communications (IRDM)?
CEO bought at ~$37; shares now ~$19. We break down Iridium’s moat, IoT and PNT/D2D bets, valuation reset, and key risks—without the rocket emojis (ok, a few).
Insiders Had Bought Shares of Elanco Animal Health (ELAN); Turns Out They Were Right — And It May Only Be the Beginning!
Insiders bought millions of Elanco shares under $15 — and they were right. Now, with JP Morgan’s upgrade and revenues rising, this stock might be a hidden gem in the animal health world. 🐾
Six Months Ago, a Director Bought Sweetgreen (SG) at Twice the Price It Trades Today — Should You Indulge?
Sweetgreen’s stock has been chopped in half, insiders are under water, and institutions somehow own more shares than exist. But with AI-powered “Infinite Kitchens,” loyal customers, and a cult brand, could this be the comeback salad of the year—or another case of tossed expectations?
Tilray of Sunshine: CEO Bought Shares Weeks Ago — and Now Earnings Are Finally Rolling In
Tilray finally posted profits and a healthy cash flow — and insiders bought in early. Could this be the long-awaited turnaround, or just another puff of smoke?
Absci: When AI Meets Antibodies — and Insiders Can’t Resist Buying More!
AI is designing drugs, and Absci is leading the charge — with insider confidence, top-tier partners, and a cash runway through 2028. Still pre-revenue but packed with promise, this biotech might just be the next NVIDIA of antibodies.